Assessment of squalene adjuvanted and non-adjuvanted vaccines against pandemic H1N1 influenza in children 6 months to 17 years of age

References

• World Health Organization. Pandemic (H1N1) 2009 – update 68. (Accessed October 9, 2009 at http://www.who.int/csr/don/2009_10_02/en/index.html)
   Google Scholar
• Chowell G, Bertozzi SM, Colchero MA, Lopez-Gatell H, Alpuche-Aranda C, Hernandez M, et al. Severe respiratory disease concurrent with the circulation of H1N1 influenza. N Engl J Med 2009; 361:674 - 9; http://dx.doi.org/10.1056/NEJMoa0904023; PMID: 19564633
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Surveillance for pediatric deaths associated with 2009 pandemic influenza A (H1N1) virus infection - United States, April-August 2009. MMWR Morb Mortal Wkly Rep 2009; 58:941 - 7; PMID: 19730406
   PubMedGoogle Scholar
• Vaillant L, La Ruche G, Tarantola A, Barboza P, epidemic intelligence team at InVS. Epidemiology of fatal cases associated with pandemic H1N1 influenza 2009. Euro Surveill 2009; 14:19309; PMID: 19712643
   PubMedGoogle Scholar
• Shinde V, Bridges CB, Uyeki TM, Shu B, Balish A, Xu X, et al. Triple-reassortant swine influenza A (H1) in humans in the United States, 2005-2009. N Engl J Med 2009; 360:2616 - 25; http://dx.doi.org/10.1056/NEJMoa0903812; PMID: 19423871
   PubMed Web of Science ®Google Scholar
• Jamieson DJ, Honein MA, Rasmussen SA, Williams JL, Swerdlow DL, Biggerstaff MS, et al, Novel Influenza A (H1N1) Pregnancy Working Group. H1N1 2009 influenza virus infection during pregnancy in the USA. Lancet 2009; 374:451 - 8; http://dx.doi.org/10.1016/S0140-6736(09)61304-0; PMID: 19643469
   PubMed Web of Science ®Google Scholar
• Perez-Padilla R, de la Rosa-Zamboni D, Ponce de Leon S, Hernandez M, Quiñones-Falconi F, Bautista E, et al, INER Working Group on Influenza. Pneumonia and respiratory failure from swine-origin influenza A (H1N1) in Mexico. N Engl J Med 2009; 361:680 - 9; http://dx.doi.org/10.1056/NEJMoa0904252; PMID: 19564631
   PubMed Web of Science ®Google Scholar
• Levie K, Leroux-Roels I, Hoppenbrouwers K, Kervyn AD, Vandermeulen C, Forgus S, et al. An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults. J Infect Dis 2008; 198:642 - 9; http://dx.doi.org/10.1086/590913; PMID: 18576945
   PubMed Web of Science ®Google Scholar
• Nolan T, Richmond PC, Formica NT, Höschler K, Skeljo MV, Stoney T, et al. Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children. Vaccine 2008; 26:6383 - 91; http://dx.doi.org/10.1016/j.vaccine.2008.08.046; PMID: 18801398
   PubMed Web of Science ®Google Scholar
• Banzhoff A, Gasparini R, Laghi-Pasini F, Staniscia T, Durando P, Montomoli E, et al. MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults. PLoS One 2009; 4:e4384; http://dx.doi.org/10.1371/journal.pone.0004384; PMID: 19197383
   PubMed Web of Science ®Google Scholar
• Vesikari T, Karvonen A, Tilman S, Borkowski A, Montomoli E, Banzhoff A, et al. Immunogenicity and safety of MF59-adjuvanted H5N1 influenza vaccine from infancy to adolescence. Pediatrics 2010; 126:e762 - 70; http://dx.doi.org/10.1542/peds.2009-2628; PMID: 20819892
   PubMed Web of Science ®Google Scholar
• Frey S, Poland G, Percell S, Podda A. Comparison of the safety, tolerability, and immunogenicity of a MF59-adjuvanted influenza vaccine and a non-adjuvanted influenza vaccine in non-elderly adults. Vaccine 2003; 21:4234 - 7; http://dx.doi.org/10.1016/S0264-410X(03)00456-0; PMID: 14505903
   PubMed Web of Science ®Google Scholar
• Vesikari T, Pellegrini M, Karvonen A, Groth N, Borkowski A, O’Hagan DT, et al. Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant. Pediatr Infect Dis J 2009; 28:563 - 71; http://dx.doi.org/10.1097/INF.0b013e31819d6394; PMID: 19561422
   PubMed Web of Science ®Google Scholar
• Garten RJ, Davis CT, Russell CA, Shu B, Lindstrom S, Balish A, et al. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science 2009; 325:197 - 201; http://dx.doi.org/10.1126/science.1176225; PMID: 19465683
   PubMed Web of Science ®Google Scholar
• World Health Organization. Characteristics of the emergent influenza A (H1N1) viruses and recommendations for vaccine development. May 26 2009. (Accessed September 23, 2009, at http://www.who.int/csr/resources/publications/swineflu/H1N1Vaccinevirusrecommendation26May2009.pdf)
   Google Scholar
• Hancock K, Veguilla V, Lu X, Zhong W, Butler EN, Sun H, et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med 2009; 361:1945 - 52; http://dx.doi.org/10.1056/NEJMoa0906453; PMID: 19745214
   PubMed Web of Science ®Google Scholar
• Nolan T, McVernon J, Skeljo M, Richmond P, Wadia U, Lambert S, et al. Immunogenicity of a monovalent 2009 influenza A(H1N1) vaccine in infants and children: a randomized trial. JAMA 2010; 303:37 - 46; http://dx.doi.org/10.1001/jama.2009.1911; PMID: 20026597
   PubMed Web of Science ®Google Scholar
• Arguedas A, Soley C, Abdelnour A, Sales V, Lindert K, Della Cioppa G, et al, Costa Rican H1N1 Vaccine Study Group. Assessment of the safety, tolerability and kinetics of the immune response to A/H1N1v vaccine formulations with and without adjuvant in healthy pediatric subjects from 3 through 17 years of age. Hum Vaccin 2011; 7:58 - 66; http://dx.doi.org/10.4161/hv.7.1.13411; PMID: 21285531
   PubMed Web of Science ®Google Scholar
• Zhu F-C, Wang H, Fang H-H, Yang JG, Lin XJ, Liang XF, et al. A novel influenza A (H1N1) vaccine in various age groups. N Engl J Med 2009; 361:2414 - 23; http://dx.doi.org/10.1056/NEJMoa0908535; PMID: 19846844
   PubMed Web of Science ®Google Scholar
• Plennevaux E, Blatter M, Cornish MJ, Go K, Kirby D, Wali M, et al. Influenza A (H1N1) 2009 two-dose immunization of US children: an observer-blinded, randomized, placebo-controlled trial. Vaccine 2011; 29:1569 - 75; http://dx.doi.org/10.1016/j.vaccine.2010.12.116; PMID: 21219979
   PubMed Web of Science ®Google Scholar
• Roman F, Vaman T, Kafeja F, Hanon E, Van Damme P. AS03(A)-Adjuvanted influenza A (H1N1) 2009 vaccine for adults up to 85 years of age. Clin Infect Dis 2010; 51:668 - 77; http://dx.doi.org/10.1086/655830; PMID: 20687838
   PubMed Web of Science ®Google Scholar
• Clark TW, Pareek M, Hoschler K, Dillon H, Nicholson KG, Groth N, et al. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med 2009; 361:2424 - 35; http://dx.doi.org/10.1056/NEJMoa0907650; PMID: 19745215
   PubMed Web of Science ®Google Scholar
• Waddington CS, Walker WT, Oeser C, Reiner A, John T, Wilkins S, et al. Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study. BMJ 2010; 340:c2649; http://dx.doi.org/10.1136/bmj.c2649; PMID: 20508026
   PubMed Web of Science ®Google Scholar
• Carmona A, Omeñaca F, Tejedor JC, Merino JM, Vaman T, Dieussaert I, et al. Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6-35 months. Vaccine 2010; 28:5837 - 44; http://dx.doi.org/10.1016/j.vaccine.2010.06.065; PMID: 20600478
   PubMed Web of Science ®Google Scholar
• Garcia-Sicilia J, Gillard P, Carmona A, Tejedor JC, Aristegui J, Merino JM, et al. Immunogenicity and safety of AS03-adjuvanted H1N1 pandemic vaccines in children and adolescents. Vaccine 2011; 29:4353 - 61; http://dx.doi.org/10.1016/j.vaccine.2011.04.011; PMID: 21504774
   PubMed Web of Science ®Google Scholar
• Nassim C, Christensen S, Henry D, Holmes S, Hohenboken M, Kanesa-Thasan N. Identification of antigen and adjuvant doses resulting in optimal immunogenicity and antibody persistence up to 1 year after immunization with a pandemic A/H1N1 influenza vaccine in children 3 to < 9 years of age. Pediatr Infect Dis J 2012; 31:e59 - 65; http://dx.doi.org/10.1097/INF.0b013e31824b9545; PMID: 22418661
   PubMedGoogle Scholar
• The World Health Organization (WHO). WHO Manual on Animal Influenza Diagnosis and Surveillance. 2002. Accessed October 21, 2009 at http://www.who.int/vaccine_research/diseases/influenza/WHO_manual_on_animal-diagnosis_and_surveillance_2002_5.pdf
   Google Scholar
• Kendal AP, Pereira MS, Skehel JJ, eds. Concepts and Procedures for Laboratory-Based Influenza Surveillance. Atlanta, GA: Centers for Disease Control and Prevention; 1982.
   Google Scholar
• Committee for Proprietary Medicinal Products (CPMP). Note for guidance on harmonisation of requirements for influenza vaccines. CPMP/BWP/214/96. The European Agency for the Evaluation of Medicinal Products (EMEA), March 1997. (Accessed September 25, 2009, at http://www.emea.europa.eu/pdfs/human/bwp/021496en.pdf)
   Google Scholar
• FDA Guidance for Industry. Toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials. September 2007. Accessed October 15, 2009 at http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm091977.pdf
   Google Scholar